TP53 and neoplasm: Pathogenic mutations in TP53 and ARID1A were the most frequently observed alterations and were distributed comparably across both the PD-L1 < 5 and ≥5 groups, suggesting these alterations are fundamental oncogenic drivers largely independent of the tumor’s immune phenotype.